AustraliaHealth

Biotech firm Patrys (ASX:PAB) announced two key appointments for its upcoming Phase 1A clinical trial of RLS-2202.

Nyrada (ASX:NYR) received a notice of allowance from the United States Patent and Trademark Office for its patent application covering Xolatryp.

BCAL Diagnostics (ASX:BDX) expands its cancer detection reach, integrating clinical referral forms into software used by 97% of Australian GPs.

BlinkLab (ASX:BB1) announced a landmark academic research agreement with the Erasmus University Medical Centre Rotterdam.

Amplia Therapeutics (ASX:ATX) initiated the first stage of a registration-enabling Phase 2b clinical trial for its drug candidate, narmafotinib.

Telix Pharmaceuticals (ASX:TLX) completed patient enrolment for its international, multicentre Phase 1 IPAX-2 clinical trial.

Alcidion Group (ASX:ALC) signed an asset sale agreement to acquire the business and assets of the 'Kyra flow products' from Telstra Health.

Racura Oncology (ASX:RAC) announced a milestone in its Phase 1 CPACS clinical trial, receiving formal clearance to escalate the dosage of its lead candidate, RC220.

AVITA Medical (ASX:AVH) reported its financial performance for the first quarter of 2026, headlined by a total revenue of US$19.3 million.

Pacific Edge (ASX:PEB) secured a regulatory win as Novitas publishes draft Medicare coverage for Cxbladder Triage tests.

Argenica Therapeutics (ASX:AGN) has formed a Clinical Advisory Committee to lead its Phase 2b trial for the neuroprotective candidate, ARG-007.

Nexalis Therapeutics (ASX:NX1) announced a clinical milestone following the final dosing of its Phase 1 study for IRX-616a.